Related parties accounts payable and accrued expenses
327,890
Research and development contract liabilities
231,342
Operating lease liabilities, current
940,775
Total current liabilities
1,500,007
Operating lease liabilities, long-term
161,019
Total liabilities
1,661,026
Common stock, 0.0001 par value authorized 100,000,000 shares issued and outstanding 15,417,444 and 8,790,102 shares at june 30, 2026 and december 31, 2025, respectively
1,541
Additional paid-in capital
86,097,966
Accumulated deficit
-62,188,147
Total lixte biotechnology stockholders equity
23,911,360
Non-controlling interest
1,076,479
Total stockholders equity
24,987,839
Total liabilities and stockholders equity
26,648,865
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.